Intercept Pharmaceuticals’ (ICPT) “Outperform” Rating Reiterated at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. restated their outperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research note published on Thursday morning. Oppenheimer Holdings, Inc. currently has a $200.00 target price on the biopharmaceutical company’s stock.
Several other equities analysts also recently weighed in on ICPT. Wedbush reiterated an outperform rating and set a $231.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, May 26th. ValuEngine upgraded Intercept Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, June 2nd. Credit Suisse Group set a $201.00 target price on Intercept Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, June 3rd. Cowen and Company reiterated a buy rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Finally, BidaskClub upgraded Intercept Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, June 23rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $207.75.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at 94.88 on Thursday. The firm’s market capitalization is $2.38 billion. Intercept Pharmaceuticals has a 12 month low of $85.88 and a 12 month high of $172.95. The company’s 50 day moving average price is $108.47 and its 200-day moving average price is $116.36.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same period in the prior year, the business posted ($3.14) earnings per share. The firm’s revenue for the quarter was up 459.6% compared to the same quarter last year. On average, equities analysts predict that Intercept Pharmaceuticals will post ($14.06) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/18/intercept-pharmaceuticals-icpt-outperform-rating-reiterated-at-oppenheimer-holdings-inc.html.
In other news, CFO Sandip Kapadia sold 1,431 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $121.59, for a total value of $173,995.29. Following the completion of the sale, the chief financial officer now owns 20,569 shares in the company, valued at $2,500,984.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO David Shapiro sold 1,250 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,013 shares of company stock valued at $6,198,747. Insiders own 4.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of ICPT. Teachers Advisors LLC grew its stake in shares of Intercept Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 1,339 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Intercept Pharmaceuticals by 223.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 8,390 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 5,800 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals in the first quarter valued at about $130,000. Bank of New York Mellon Corp grew its stake in shares of Intercept Pharmaceuticals by 10.2% in the first quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock valued at $7,725,000 after buying an additional 6,312 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Intercept Pharmaceuticals by 24.7% in the first quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock valued at $566,000 after buying an additional 990 shares in the last quarter. Institutional investors and hedge funds own 82.19% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.